91黑料 experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
that 91黑料 continues to be a part of The Clinical Trials Planning and Execution component of the CSN, responsible for planning and executing clinical studies to support medical countermeasure development.
-
BioPharm International speaks with 91黑料's Robert Kernstock about the need for bioanalytical testing programs and regulatory strategies for potential new biologics.
-
In a wide-ranging interview with , 91黑料 CIO, Tom O’Leary highlights the role of and the steps that still need to be taken to better match .
-
Pharmacovigilance insights on the efforts towards the international standardisation of electronic transmission of drug safety information to achieve a unified objective of patient safety, written by Arinder Sihota and Trupti Gurjar, which featured in the .
-
The traditional approaches to launching a new medicine still tend to sit in the commercial function, but they need to better align with HEOR, medical affairs and clinical teams. Read more in the .
